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Abstract 
Goal 
Invasive vagus nerve stimulation (VNS) has the potential to enhance the effects of 
physiotherapy for upper limb motor recovery post stroke. Noninvasive, trans-auricular branch 
VNS (taVNS) may have similar benefits but this has not been evaluated in stroke recovery. 
We sought to determine the feasibility of transcutaneous auricular VNS (taVNS) delivered 
alongside upper limb repetitive task-specific practice post stroke and its effects on a range of 
outcome measures evaluating limb function.  
Materials and Methods 
Thirteen participants >3 months post ischemic stroke with residual upper limb dysfunction 
were recruited from the community of Sheffield, UK (October - December 2016). 
Participants underwent 18 x 1-hour sessions over 6 weeks in which they made 30-50 
repetitions of 8-10 arm movements concurrently with taVNS (NEMOS®, Cerbomed, 25 Hz, 
0.1 ms pulse width) at maximum tolerated intensity (mA). An electrocardiogram and 
rehabilitation outcome scores were obtained at each visit. Qualitative interviews determined 
the acceptability of taVNS to participants.  
Results 
Median time post-stroke was 1.16 years and baseline median/IQR Upper limb fugl-meyer 
(UFM) was 63 (54.5-99.5). Participants attended 92% of the planned treatment sessions. 
Three participants reported side effects, mainly fatigue, but all performed mean of >300 arm 
repetitions per session with no serious adverse events. There was a significant change in the 
UFM with a mean increase per participant of 17.1 points (SD 7.8).  
Conclusion 
  
taVNS is feasible and well tolerated alongside upper limb repetitive movements in post 
stroke rehabilitation. The motor improvements observed justify a Phase 2 trial in patients 
with residual arm weakness. 
 
 
  
Introduction 
Approximately half of stroke survivors have persisting arm weakness, which significantly 
impedes activities of daily living. Upper limb interventions to enhance neuroplasticity post 
stroke usually involve “repetitive task-specific practice” (RTP) in which the patient makes 
repeated movements of the arm directed towards a functional goal.  
Mounting evidence from animal and human studies suggest that stimulation of the vagus 
nerve (VNS) enhances the effects of RTP by boosting neuroplasticity. In rats with ischaemic 
stroke, delivery of VNS concurrently with “pulls” of a lever to obtain food led to more rapid 
recovery of the stroke-affected forelimb.
 12 
These improvements were associated with an 
enlargement of the associated motor cortex.
3 
Delivery of VNS concurrently with a stimulus 
can also treat tinnitus (a condition caused by maladaptive plasticity), where the pairing of 
VNS with different auditory tones can reduce the person’s perception of the unwanted 
sound
4
.  
Several mechanisms may explain the beneficial effects of VNS on plasticity. 
5
 For example, 
VNS increases levels of brain-derived neurotrophic factor (BDNF), and IL-B (both key 
regulators of neuroplasticity).
56
 VNS also stimulates the release of acetylcholine (ACh) and 
noradrenaline.
7
 One study in mice post stroke found that selective obliteration of the 
cholinergic cortical projections from the Nucleus Basilis completely offset the effects of VNS 
on limb movement 
8
 suggesting a key role for ACh in mediating plasticity from VNS. 
VNS is already a licensed treatment in humans for epilepsy and depression. In these cases, 
stimulators are implanted directly onto the vagus nerve. This “invasive” VNS was also used 
in a recent pilot trial of VNS in 20 human stroke survivors with arm weakness.
9
 In that trial, 
participants were randomised in a cross-over trial to either 6 weeks of intensive repetitive 
  
task practice (RTP) paired with VNS or RTP alone. In the per-protocol analysis, the VNS 
group improved their Upper Extremity Fugl-Meyer (UFM) score  by 9.6 points compared to 
only 3.0 in the RTP-only group (between-group difference 6.5 points, 95% CI 0.4-12.6; P 
=0.04).
10
 Whilst such results are encouraging, recruitment into such studies can be 
challenging for many stroke survivors are unfit for, or are reluctant to undergo surgery.  
Recently, devices that can stimulate the vagus nerve non-invasively have become available. 
One device, called NEMOS
R
 (Cerbomed, Germany) when placed in the horizontal depression 
of the outer ear (the “concha”) (Figure 1) stimulates the “auricular branch” of the vagus 
nerve. Functional magnetic resonance brain imaging (fMRI) studies have demonstrated that 
transcutaneous auricular VNS (taVNS) activates the same areas within the brain as surgically 
implanted VNS (i.e. the Nucleus Tractus Solitarius, the Locus Coeruleus and the Nucleus 
Accumbens)
11
 suggesting equivalent mechanisms of action. 
Transcutaneous auricular VNS devices are also well tolerated by patients with diseases such 
as migraine and epilepsy, with no serious adverse reactions having been reported in clinical 
trials to date. However, taVNS has not yet been tested in the context of stroke recovery.  
We aimed to determine the feasibility, tolerability, acceptability and safety of taVNS 
alongside RTP in stroke survivors with arm weakness following a stroke. We also determined 
the responsiveness-to-change of a range of rehabilitation outcome measures. Our findings 
will be used to inform the design of a future randomized trial of taVNS in stroke recovery. 
  
Materials and Methods 
This was a single-group pre-post intervention study. The protocol was approved by Sheffield 
Research Ethics Committee (ref 15/YH/0397). The study design conformed to the 
CONSORT-statement extension for pilot and feasibility studies (http://consort-
statement.org). The study was registered at ClinicalTrials.gov (reference NCT03170791). All 
participants gave written informed consent for the study. 
Participants 
Eligible participants were screened, approached and recruited by weekly liaison with 
Community Stroke Service in Sheffield, UK between October -December 2016. All study 
treatments took place at the Clinical Research Facility at the Northern General Hospital, 
Sheffield. Participants were eligible if they (1) were over 18 years of age, (2) had an anterior 
circulation ischaemic stroke at least 3 months previously, (3) had active shoulder abduction 
and finger flexion. No strict cut-offs were required for baseline upper limb function as long as 
the participant could engage with the therapist and perform the limb movements. Participants 
were not eligible if they: (1) had impairments of upper limb function other than those caused 
by stroke, (2)  were participating in any other research trial (3) had aphasia or cognitive 
difficulties severe enough to interfere with the informed consent process, task specific 
practice or communication of adverse events, (4) were pregnant or trying to get pregnant, (5) 
had a pacemaker or other implanted electrical device or (6) had severe spasticity (a Modified 
Ashworth Score
12
 ≥3).  
Sample size 
 
  
We aimed to recruit a minimum of 12 participants as this is the minimum number required 
for a pilot/feasibility study
13
.  
Outcome Measures 
At the initial study visit, demographics, time since stroke, medication and vascular risk 
factors were obtained from participants. Hospital records and imaging results were viewed to 
record the size, location and precise date of the stroke. Two measures of upper limb 
movement and functional independence were assessed by the study physiotherapists: Upper 
Limb Fugl-Meyer (UFM) 
14
 and Action Recovery Arm Test (ARAT)
15,16
. The participants 
also completed the following self-report measures: Modified Rankin Score (mRS),
17
 Barthel 
Index,
18
 Stroke Impact Scale (SIS),
19
 Motor Activity Log (to measure use of the impaired 
limb in a variety of activities of daily living such as putting on shoes, drying hands, wiping a 
kitchen counter, using a television remote-control),
20
 Patient-health Questionnaire (PHQ9)
21
, 
Generalised Anxiety Disorder 7 (GAD7)
22
 and the Fatigue Assessment Scale
23
. The upper 
limb assessment scales was chosen because they capture the three domains of the 
International Classification of Functioning framework (impairment, function and 
participation) and incorporate objective as well as patient-reported outcome measures.  Mood 
and anxiety were assessed as depression is a common complication of stroke and can impede 
rehabilitation as well as being potentially moderated by VNS.
24
 All outcomes were measured 
again at the final treatment visit.  
An electrocardiogram (ECG) was performed at baseline and at the end of each treatment 
session and the pulse (beats/min) rate, PR interval (ms), QRS duration (ms) and the corrected 
QT interval (ms) were recorded by the ECG machine. These were reviewed by JR and 
compared to baseline values. At each treatment visit, details of any side effects or difficulties 
experienced by participants during or after the intervention were recorded.  
  
Intervention 
The taVNS ear piece was fitted to the participants left ear such that the electrodes made 
contact with the concha (Figure 1). The intensity (mA) of stimulation was increased slowly 
by increments of 0.1 mA until the participant’s reported maximum tolerable level and this 
intensity used for the rest of the session. The manufacturers (Cerbomed, Germany) 
reprogrammed the stimulator to avoid the usual “ramp-up” (increase in mA) each time it was 
switched on. The pulse width was 0.1 ms and frequency 25 Hz. 
Exercise programmes were tailored to the participant’s impairments and goals. Each session 
began with large- range arm movements, frequently involving bilateral activities, either 
reciprocal or symmetrical and using equipment e.g. pedals, a pole or ball to assist 
independent movement. This was followed by repetitive task-specific movements e.g. turning 
cards, manipulating or lifting objects, opening and closing bottles (Table 1).  
Approximately 7 - 10 tasks with 30 to 50 repetitions were attempted (aiming for > 300 
repetitions in total) per session. 
25
 The physiotherapist turned the stimulation “on” by pressing 
a button on the stimulator unit when the participant began to move the arm and “off” when 
the movement ceased. The frequency of sessions (3 times a week for 6 weeks) matched that 
used in the trial of invasive VNS
12
 which reported improvements in function post stroke. 
The number of arm movements per session were recorded.  
Qualitative interviews 
After the final treatment session, a semi-structured interview was conducted.  The topic guide 
incorporated open-ended questions regarding the acceptability of the electrical stimulation. 
The interviews allowed participants to share experiences that the researchers had not 
anticipated.
26
 Interviews lasted 30-45 minutes and were recorded and transcribed verbatim.   
  
Data analysis 
Analyses were mainly descriptive, as the study was not powered for inferential analysis. We 
calculated the proportion of participants who completed the 6- week intervention, the mean 
number of arm movements per hour for each participant, and the proportion of invited 
therapy sessions attended. Details of any adverse events were recorded at each visit and were 
coded according to NHS Research Authority definitions (where serious adverse event is 
defined as any event resulting in hospitalization, significant disability or death, is life-
threatening, a congenital defect or requiring intervention)
27
. The proportion of participants 
reporting minor side effects or adverse reactions to taVNS was determined from the interview 
responses. Where there existed a proposed Minimal Clinically Important Difference (MCID) 
for a scale, we calculated the number of participants who achieved this change (e.g. for the 
Upper-limb fugl-meyer, MCID = 10 points)
28
, and for ARAT (5.7 points))
29
.  
We calculated effect sizes (Cohen’s d) for each measure using the following formula: (mean 
post-intervention minus mean at-baseline) divided by the standard deviation at baseline.  
We regarded a meaningful change in the ECG parameters to be a) a change of 20% in resting 
heart rate and/or b) a 10% change from baseline PR/QRS or QTc or c) a deviation outside the 
normal reference range for any of these values or d) the development of a non-sinus rhythm 
Qualitative data were analysed with a thematic framework approach
30
. Transcripts were first 
coded according to themes decided a priori that were focused on the specific aims of the 
study, such as experience of the stimulation, experience of the physiotherapy and wider 
experiences of the study. Data relating to each theme was placed into a matrix enabling data 
for each participant and each theme to be carefully compared. Transcripts were then checked 
  
to ensure there were no elements were overlooked by the pre-existing themes. The themes 
arising and the analytical process were examined by a second reviewer to ensure rigour.  
Criteria for Proceeding to a definitive trial 
Pre-specified success criteria included the following: 1) More than 2/3 planned treatment 
sessions attended 2) All participants achieving mean task repetitions per session >300 3) <1/3 
participants experiencing side effects from intervention 4) absence of serious adverse events. 
 
  
Results 
Twenty interested participants were contacted. After telephone screening, 18 were invited for 
further assessment. Of these, 13 met inclusion criteria (Figure 2). Reasons for exclusion 
included spasticity (n=2), aphasia (n=1) and absence of active arm movement (n=2).   
The 13 participants [(10 males, mean (SD) age 64.5 (6.9), median (IQR) years since stroke 
1.16 (IQR 0.7-3.6), median (IQR) baseline total UFM 63 (54.5-99.5)] underwent a combined 
total of 215 therapy sessions. This equated to 92% of the total expected sessions. One 
participant withdrew after her 5
th
 visit because the sessions were too constraining on her time. 
Another participant missed 6 sessions part way through due to a bereavement but returned to 
complete the remaining sessions so her data were included in the final analysis. The other 11 
participants completed the entire treatment course of 18 sessions (Figure 3).  
The median (range) intensity of taVNS delivered was 1.4 (1-3.2) mA. The mean (SD) 
number of arm movements per 1-hour session was 464 (70) with all 12 participants achieving 
at least 300 arm movements per hour.  Table 1 shows the type and number of arm repetitions 
performed by one participant as they progressed through the programme.   
Only three participants reported side effects. These included light-headedness in one 
participant and general tiredness and fatigue in two. Only the former was considered by the 
researchers to be possibly attributed to the taVNS. No associated ECG changes were seen.  
Table 2 shows the outcome measurements at Visit 18 compared to baseline. Four measures 
showed improvement. The mean (SD) improvement in UFM from baseline to Visit 18 was 
17.1 (SD 7.8) with 10 participants (83%) achieving an increase of >10 points (the minimum 
clinically important difference) and an overall effect size of 0.68. The mean (SD) ARAT 
increased by 2.5 (3.6) points (effect size 0.10), the mean MAL by 3.4 (11) points (effect size 
  
0.04) and the mean SIS by 5.6 points (14.1) (effect size 0.17). The reported MCID for ARAT 
(5.7) was achieved by 3 (25%) participants. The other outcome measures changed very little 
or not at all (Table 2). There were no significant changes in ECG recordings for rate, PR/QRS 
or QTc interval. 
Qualitative Interviews 
Two key themes were the experience of the intervention, (the perceived advantages of the 
intervention. 
The experience of the intervention. 
Most participants felt that the electrical stimulation was comfortable. Only one participant 
felt that the sensation stung when it was turned up too high.  
Most participants were happy with the frequency and duration of visits. Some participants 
commented that the exercises were tiring. 
The participant complaining of light-headedness was uncertain if this was related to the 
taVNS. He and two others reported tiredness and some muscle stiffness but all three believed 
this was related to the intensity of the exercise programme rather than the taVNS. 
Perceptions of effectiveness 
Eleven out of the twelve participants felt that they had improved upper limb function, 
mentioning e.g. improved dexterity, strength and/or flexibility with tasks such as putting a 
coat on, brushing hair and gripping objects in the kitchen.  
“You know it all used to be really terribly heavy; it was an effort to lift it because it was 
heavy and now I can, I can do it” 
  
Discussion 
We recruited 13 participants who between them attended 215 treatment sessions in which 
transcutaneous auricular VNS (taVNS) was delivered concurrently with repetitive task 
practice (RTP). Only one participant withdrew from the study. Despite the added treatment 
with taVNS, all 12 remaining participants were able to perform >300 arm movements per 
hour - the threshold which triggers plasticity in animal models. 
25
 The treatment was 
generally well tolerated and almost all felt that their arm function improved during the study. 
Of the 9 outcome measures we assessed, the UFM was the most sensitive to change (Table 
2), increasing by a mean (SD) of 17 (7.8) points. The UFM scale measures the “impairment” 
domain of the International Classification of Functioning and is designed specifically for use 
in post-stroke hemiplegia, measuring actual recovery rather than compensatory movement.
31
 
UFM was also the outcome which improved significantly in the trial of invasive VNS in 
stroke motor recovery 
9
 and has been recently deemed a core outcome in stroke recovery.
32
 
Transcutaneous VNS has the advantage over invasive VNS in that it does not require surgery. 
Furthermore, whilst invasive VNS can cause cough, hoarseness, voice alteration and 
parenthesis
33
, to our knowledge there have been no reports of serious adverse reactions to 
taVNS in the literature to date. Our high retention rate and the positive feedback from 
participants further suggest that a future trial of taVNS in stroke recovery is feasible. 
There were, however some potential limitations to this study. First, it would have been 
preferable to conduct the qualitative interviews with a researcher not directly involved in the 
therapy. However, the participants were open in describing suboptimal aspects of the 
programme and felt immediately at ease being interviewed by a familiar researcher. Second, 
at this stage we can only speculate about the size of any beneficial effect of the taVNS 
  
combined with RTP alone. However, a recent Cochrane review (11 trials, 749 participants) 
found that RTP alone produced surprisingly modest improvements in arm function post 
stroke regardless of time interval since stroke.
34
 In that review, the standardized mean 
difference (i.e. the mean effect size taking into consideration differences in motor outcome 
scales between studies) for RTP versus usual care/placebo was 0.25 (95% confidence interval 
(CI) 0.01 to 0.49).
34
 In contrast, we observed an effect size for UFM of 0.68 with 10/12 
participants achieving an increase of at least 10 points in UFM score. Our findings are thus in 
keeping with a potentially powerful effect of taVNS but this needs to be further tested in a 
controlled trial setting. Such a trial could deploy “sham” taVNS  by inverting the electrodes 
in the ear
35
 which does not activate central vagal connections.
35
  
A further limitation is that the intensity of RTP was greater than that given in clinical practice 
by physiotherapists in the UK. However, taVNS may in future be self-administered by 
patients allowing frequent sessions at low cost. Furthermore, the advantage of treating 
participants in a clinical research facility as done here, was to ensure adherence to the 
treatment protocol.   
taVNS appears to be a safe, feasible, and acceptable treatment for stroke survivors 
undergoing RTP for the upper limb. The improvements in arm function were greater than 
expected based on of RTP-alone.  A Phase 2 clinical trial is warranted to establish the 
efficacy of taVNS for recovery of the upper limb post stroke.
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Table 1 Practice programme for Participant 005 showing number of repetitions of each arm movement. 
 Visit number  
Activity 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Total 
Gleniohumeral joint 
(GHJ) flexion  
80 60 60         30 30      260 
Elbow extension 80 60 60         30 30     30 320 
Forearm supination / 
pronation 
80 80 60 60 60 40 40 40 40 40 60 40 40 40 40 40 40 30 870 
Wrist extension 80 80 60  40 40 40 40 40 40 30 40 40 30 30 30 30 30 720 
Arm cycle forwards  40 40 50 50 80 100 100 100 100 100 100 100 120 120 150 150 150 1650 
Arm cycle backwards  20 20 30 30 40 50 50 60 80 100 100 100 100 120 120 120 150 1290 
Walking pole-
direction 
  40 60 60 60 60 60  40 40   40 40 40 40  580 
Sliding towel    60 60 60 80 80 100 60 60 60 60 60 60 80 80 80 1040 
Pushing gym ball 
bilaterally 
   60 40 40   40 40     40    260 
GHJ external / 
internal rotations  
   20 40 40 40 40 50 50 50 60 60 40  40 40 30 600 
    Total movements 320 340 340 340 380 400 410 410 430 450 440 460 460 430 480 500 500 500 7590 
 
 
 
  
Table 2 showing baseline and Visit 18 scores for outcome assessments and mean (SD) change (across all 12 participants) 
 Baseline visit Final intervention 
visit (end of week 6) 
  
Outcome 
measure* 
Mean (SD) Mean (SD) Mean (SD) 
Change in score†  
Effect size 
UFM 71.2 (25.3) 88.3 (23.1) 17.1 (7.8) 0.68 
ARAT 21.3 (25.2) 23.8 (26.9) 2.5 (3.6) 0.10 
MAL 68.6 (89.6) 72 (86.2) 3.4 (11.0) 0.04 
SIS 207.4 (33.6) 213 (33.2) 5.6 (14.1) 0.17 
FAS 23.2 (4.6) 21.4 (4.8) 1.8 (5.1) 0.41 
PHQ9 5.5 (7.1) 4.2 (1.5) 1.3 (2.9) 0.18 
GAD7 3 (4.2) 2.5 (3.6) 0.5 (1.2) 0.12 
mRS 2.67 (0.65) 2.67 (0.65) 0 0 
BI 17.3 (2.8) 17.3 (2.8) 0 0 
 
*UFM= Upper Limb Fugl-Meyer score, ARAT= Action Recovery Arm Test, mRS= Modified Rankin Score
17
 BI= Barthel Index 
18
, 
SIS=Stroke Impact Scale,
19
 MAL= Motor Activity Log,
20
 PHQ9= Patient-health Questionnaire-9
21
, GAD7= Generalised Anxiety 
Disorder 7
22
 and FAS= Fatigue Assessment Scale
23
. † change shown in direction of improvement in function/mood etc 
